[go: up one dir, main page]

WO2009050726A3 - Compositions and methods for improved delivery of bupropion - Google Patents

Compositions and methods for improved delivery of bupropion Download PDF

Info

Publication number
WO2009050726A3
WO2009050726A3 PCT/IN2008/000337 IN2008000337W WO2009050726A3 WO 2009050726 A3 WO2009050726 A3 WO 2009050726A3 IN 2008000337 W IN2008000337 W IN 2008000337W WO 2009050726 A3 WO2009050726 A3 WO 2009050726A3
Authority
WO
WIPO (PCT)
Prior art keywords
bupropion
present
micronized
nasal
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IN2008/000337
Other languages
French (fr)
Other versions
WO2009050726A2 (en
Inventor
Amarjit Singh
Sarabjit Singh
Korlakunte Prasad
Rajesh Jain
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Panacea Biotec Ltd
Original Assignee
Panacea Biotec Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Panacea Biotec Ltd filed Critical Panacea Biotec Ltd
Publication of WO2009050726A2 publication Critical patent/WO2009050726A2/en
Publication of WO2009050726A3 publication Critical patent/WO2009050726A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention provides a pharmaceutical composition comprising micronized bupropion having controlled particle size in the range between 1-60 μm. The pharmaceutical composition of the present invention comprises micronized bupropion having median particle size less than 40 micron, which exhibits outstanding bioavailability via nasal and pulmonary route even without any need for blending the micronized bupropion with large carrier particles. The composition of the present invention comprises micronized bupropion -and one or more pharmaceutically acceptable carriers, surfactants, a dispersing agents, or dispersants, which can be administered in an aerosol formulation as a dry powder for nasal and pulmonary inhalation. Particularly, the composition of the present invention for nasal delivery comprises bioadhesive microparticles of bupropion and carbohydrates like pullulan to prevent and treat diseases such as depression, premenstrual syndrome, premature ejaculation and as an aid to smoking cessation. The invention also provides a process of preparing the compositions of the present invention.
PCT/IN2008/000337 2007-05-28 2008-05-28 Compositions and methods for improved delivery of bupropion Ceased WO2009050726A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN989/MUM/2007 2007-05-28
IN989MU2007 2007-05-28

Publications (2)

Publication Number Publication Date
WO2009050726A2 WO2009050726A2 (en) 2009-04-23
WO2009050726A3 true WO2009050726A3 (en) 2009-06-25

Family

ID=40567899

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2008/000337 Ceased WO2009050726A2 (en) 2007-05-28 2008-05-28 Compositions and methods for improved delivery of bupropion

Country Status (1)

Country Link
WO (1) WO2009050726A2 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12109178B2 (en) 2013-11-05 2024-10-08 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11534414B2 (en) 2013-11-05 2022-12-27 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US12194006B2 (en) 2013-11-05 2025-01-14 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11969421B2 (en) 2013-11-05 2024-04-30 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11433067B2 (en) 2013-11-05 2022-09-06 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
EP2896400A1 (en) 2014-01-17 2015-07-22 Université Catholique De Louvain Method for increasing the bioavailability of inhaled compounds
US11844859B2 (en) 2017-08-20 2023-12-19 Nasus Pharma Ltd. Dry powder compositions for intranasal delivery
EP3668490A4 (en) * 2017-08-20 2021-06-09 Formulex Pharma Innovations Ltd. DRY POWDER COMPOSITIONS FOR INTRANASAL ADMINISTRATION
CN109771397B (en) * 2019-02-24 2021-09-28 谭淞文 Equipment integration and method for improving pulmonary inhalation medication through lactose micropowder predeposition
GB202001906D0 (en) * 2020-02-12 2020-03-25 Nasaleze Patents Ltd Compositions And Applications Thereof
US12472156B2 (en) 2020-06-05 2025-11-18 Antecip Bioventures Ii Llc Compounds and combinations thereof for treating neurological and psychiatric conditions
US12433884B2 (en) 2020-06-05 2025-10-07 Antecip Bioventures Ii Llc Compounds and combinations thereof for treating neurological and psychiatric conditions
WO2022119981A1 (en) 2020-12-01 2022-06-09 Antecip Bioventures Ii Llc Bupropion and dextromethrophan for reduction of suicide risk in depression patients
US12156914B2 (en) 2022-06-30 2024-12-03 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising bupropion and cysteine
US20240000729A1 (en) * 2022-06-30 2024-01-04 Axsome Therapeutics, Inc. Microparticles containing bupropion
US12036191B1 (en) 2022-06-30 2024-07-16 Antecip Bioventures Ii Llc Treatment of poor metabolizers of dextromethorphan with a combination of bupropion and dextromethorphan
US11717518B1 (en) 2022-06-30 2023-08-08 Antecip Bioventures Ii Llc Bupropion dosage forms with reduced food and alcohol dosing effects
US11730706B1 (en) 2022-07-07 2023-08-22 Antecip Bioventures Ii Llc Treatment of depression in certain patient populations
US11844797B1 (en) 2023-04-20 2023-12-19 Antecip Bioventures Ii Llc Combination of dextromethorphan and bupropion for treating depression
US12194036B2 (en) 2022-07-07 2025-01-14 Antecip Bioventures Ii Llc Combination of dextromethorphan and bupropion for treating depression

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002094232A1 (en) * 2001-05-24 2002-11-28 Alexza Molecular Delivery Corporation Delivery of antidepressants through an inhalation route
WO2003035137A2 (en) * 2001-10-19 2003-05-01 Respirics, Inc. Method and apparatus for dispensing inhalator medicament
WO2007002597A2 (en) * 2005-06-27 2007-01-04 Biovail Laboratories International S.R.L. Modified-release formulations of a bupropion salt
US20070043030A1 (en) * 2003-09-15 2007-02-22 Vectura Limited Pharmaceutical compositions for treating premature ejaculation by pulmonary inhalation
US20070178166A1 (en) * 2005-12-15 2007-08-02 Acusphere, Inc. Processes for making particle-based pharmaceutical formulations for pulmonary or nasal administration

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002094232A1 (en) * 2001-05-24 2002-11-28 Alexza Molecular Delivery Corporation Delivery of antidepressants through an inhalation route
WO2003035137A2 (en) * 2001-10-19 2003-05-01 Respirics, Inc. Method and apparatus for dispensing inhalator medicament
US20070043030A1 (en) * 2003-09-15 2007-02-22 Vectura Limited Pharmaceutical compositions for treating premature ejaculation by pulmonary inhalation
WO2007002597A2 (en) * 2005-06-27 2007-01-04 Biovail Laboratories International S.R.L. Modified-release formulations of a bupropion salt
US20070178166A1 (en) * 2005-12-15 2007-08-02 Acusphere, Inc. Processes for making particle-based pharmaceutical formulations for pulmonary or nasal administration

Also Published As

Publication number Publication date
WO2009050726A2 (en) 2009-04-23

Similar Documents

Publication Publication Date Title
WO2009050726A3 (en) Compositions and methods for improved delivery of bupropion
WO2005025535A3 (en) Methods for preparing pharmaceutical compositions
UA107499C2 (en) DRY POWDER COMPOSITION CONTAINING ANTIMUSCARIN
WO2006108556A3 (en) Pharmaceutical aerosol composition
WO2008053253A3 (en) Inhaler devices and bespoke pharmaceutical compositions
WO2008084312A3 (en) Micronised particles of low-dosage strength active agents for powder formulations for inhalation
FI20002215A0 (en) Combination Particles
WO2010015665A3 (en) Parenteral composition comprising microspheres with a diameter between 10 and 20 microns
WO2008079464A8 (en) Stable powder formulations of alum-adsorbed vaccines
WO2007070851A3 (en) Processes for making particle-based pharmaceutical formulations for pulmonary or nasal administration
WO2012016889A3 (en) Dry powder formulation comprising a phosphodiesterase inhibitor
BRPI0408047A (en) medicine containing a highly potent long-acting beta2 agonist in combination with other active ingredients
RU2014140539A (en) Aggregated Particles
NZ627837A (en) Dry powder formulation comprising a corticosteroid and a beta-adrenergic for administration by inhalation
MY175781A (en) Composition comprising at least two dry powders obtained by spray drying to increase the stability of the formulation
MY159172A (en) Inhalable particles comprising tiotropium
HK1203149A1 (en) Novel dosage form and formulation of abediterol
WO2009122301A3 (en) Rasagiline mesylate particles and process for the preparation thereof
MX2017004476A (en) Composition comprising at least one dry powder obtained by spray drying to increase the stability of the formulation.
WO2010111264A3 (en) Rasagiline formulations
WO2010057214A3 (en) Nanoparticles and porous particles and methods of making the same
AU2014226192A8 (en) Dry pharmaceutical compositions comprising active agent nanoparticles bound to carrier particles
TW200640459A (en) Particulate-stabilized injectable pharmaceutical compositions of posaconazole
IN2013MU01177A (en)
WO2004017942A8 (en) Inhalation compositions with high drug ratios

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08839592

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08839592

Country of ref document: EP

Kind code of ref document: A2